FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* FROST PHILLIP MD ET AL					ibol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director _X_ 10% Owner				
(Last) (First) (Middle) OPKO HEALTH, INC., 4400 BISCAYNE BLVD.		Transactio	n (M	onth/Day/	Year)		X Officer (give title below) Other (specify below) CEO & Chairman			
(Street) MIAMI, FL 33137			nal F	iled(Month/l	Day/Year	·)	6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X_ Form filed by More than One Reporting Person			
(Zip)	Table I - Non-Derivative Securities Acqui						ired. Disposed of, or Beneficially Owned			
2. Transaction Date (Month/Day/Year)	any		tion				5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	Form:	Beneficial	
	(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)		Ownership (Instr. 4)	
							3,068,951	D		
05/31/2022		P		500	A	\$ 3	196,007,194	I	See Footnote	
05/31/2022		P		12,200	A	\$ 3.005	196,019,394	I	See Footnote	
05/31/2022		P		1,900	A	\$ 3.015	196,021,294	I	See Footnote	
05/31/2022		P		5,031	A	\$ 3.02	196,026,325	I	See Footnote	
05/31/2022		P		8,130	A	\$ 3.025	196,034,455	I	See Footnote	
05/31/2022		P		8,181	A	\$ 3.03	196,042,636	I	See Footnote	
05/31/2022		P		6,958	A	\$ 3.035	196,049,594		See Footnote	
05/31/2022		P		5,400	A	\$ 3.04	196,054,994	I	See Footnote	
05/31/2022		P		1,200	A	\$ 3.045	196,056,194		See Footnote	
05/31/2022		P		500	A	\$ 3.05	196,056,694	I	See Footnote	
							30,127,177		See Footnote	
	(Middle) SISCAYNE (Zip) 2. Transaction Date (Month/Day/Year) 05/31/2022 05/31/2022 05/31/2022 05/31/2022 05/31/2022 05/31/2022 05/31/2022	OPKO HEALT 3. Date of Earliest 05/31/2022 4. If Amendment, (Zip) Ta 2. Transaction Date (Month/Day/Year) 05/31/2022 05/31/2022 05/31/2022 05/31/2022 05/31/2022 05/31/2022 05/31/2022	OPKO HEALTH, INC. 3. Date of Earliest Transaction 05/31/2022 4. If Amendment, Date Origin 22. Transaction Date Execution Date, if any (Month/Day/Year) 2. Transaction Date Execution Date, if any (Month/Day/Year) Code 05/31/2022 P 05/31/2022 P	OPKO HEALTH, INC. [OF 18 1 1 1 1 1 1 1 1 1	OPKO HEALTH, INC. [OPK]	OPKO HEALTH, INC. [OPK]	OPKO HEALTH, INC. [OPK] 3. Date of Earliest Transaction (Month/Day/Year) (Zip) 4. If Amendment, Date Original Filed(Month/Day/Year) (Zip) Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 8) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (A) or Disposed of (D) (Instr. 8) (B) Original File (Instr. 8) (A) Solution (D) Original File (Instr. 8) (B) Original File (Instr. 8) (B)	OPKO HEALTH, INC. [OPK] Subjected Properties Transaction (Month/Day/Year) OS/31/2022 A. If Amendment, Date Original Filed Month/Day/Year) CEO & Chain Chain CEO & Chain Chain	OPKO HEALTH, INC. [OPK] 3. Date of Earliest Transaction (Month/Day/Year) 18CAYNE 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original FiledMonth/Day/Year) 4. If Amendment, Date Original FiledMonth/Day/Year) 7	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned															
	(e.g., puts, calls, warrants, options, convertible securities)															
1. 7	Title of	2.	3. Transaction	3A. Deemed	4.		5.		6. Date Exer	cisable	7. Tit	le and	8. Price of	9. Number of	10.	11. Nature
Dei	rivative	Conversion	Date	Execution Date, if	Transact	tion	Number and Exp		and Expirati	on Date	Amount of		Derivative	Derivative	Ownership	of Indirect
Sec	urity	or Exercise	(Month/Day/Year)	any	Code		of	(Month/Day/Year)		Unde	rlying	Security	Securities	Form of	Beneficial	
(Ins	str. 3)	Price of		(Month/Day/Year)	(Instr. 8))	Deriv	rivative		Secur	rities	(Instr. 5)	Beneficially	Derivative	Ownership	
		Derivative					Secui	Securities		(Instr. 3 and			Owned	Security:	(Instr. 4)	
		Security					Acquired				4)				Direct (D)	
							(A) or								or Indirect	
							Disposed							Transaction(s)	\ /	
								of (D)					(Instr. 4)	(Instr. 4)		
								(Instr. 3,								
							4, and	4, and 5)								
												Amount				
									Data	Everination		or				
									Date Exercisable	Expiration	Title N	Number				
									Exercisable	Date	of					
					Code	V	(A)	(D)				Shares				

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
FROST PHILLIP MD ET AL OPKO HEALTH, INC. 4400 BISCAYNE BLVD. MIAMI, FL 33137	X	X	CEO & Chairman					
Frost Gamma Investments Trust 4400 BISCAYNE BLVD. MIAMI, FL 33137		X						

Signatures

Phillip Frost, M.D., Individually and as Trustee	06/01/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole

- (1) shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

JOINT FILER INFORMATION

Name: Frost Gamma Investments Trust

Address: 4400 Biscayne Blvd. Miami, FL 33137

Designated Filer: Phillip Frost, M.D.

Issuer Name and Ticker Symbol: OPKO Health, Inc. (OPK)

Date of Earliest Transaction: May 31, 2022

Relationship to Issuer: 10% Owner

FROST GAMMA INVESTMENTS TRUST

By: /s/ Phillip Frost, M.D., as Trustee Phillip Frost, M.D., Trustee